ScripVertex remains bullish on prospects for developing curative, endogenous insulin-sparing cell therapies for type 1 diabetes, despite disappointing results unveiled on 28 March that led the Boston-based
ScripNews that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
Pink SheetEngland’s health technology assessment (HTA) agency, NICE, has formally agreed to reimburse Vertex / CRISPR Therapeutics AG ’s CRISPR/Cas9-based gene editing therapy Casgevy (exagamglogene autotemcel